reports
- ABGSC Shipping & Transport Research
- Oliver Dunvold
- Petter Haugen
NVIDIA Robotics Adopted by Industry Leaders for Development of Tens of...
NVIDIA Robotics Adopted by Industry Leaders for Development of Tens of Millions of AI-Powered Autonomous Machines BYD Electronics, Siemens, Teradyne Robotics and Intrinsic, an Alphabet Company, Using NVIDIA Isaac Robotics Platform for Autonomous Robot Arms, Humanoids, Mobile Robots TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced that the world’s leaders in robot development are adopting the for the research, development and production of the next generation of AI-enabled autonomous machines and robots. BYD Electronics, Siemens, Teradyne Robotics an...
Robotic Factories Supercharge Industrial Digitalization as Electronic ...
Robotic Factories Supercharge Industrial Digitalization as Electronic Makers Adopt NVIDIA AI and Omniverse NVIDIA Omniverse, Isaac and Metropolis Enable Delta Electronics, Foxconn, Pegatron, Wistron to Digitally Build, Simulate and Operate Factory Digital Twins TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced that major Taiwanese electronics makers are using the company’s technology to transform their factories into more autonomous facilities with a new reference workflow. The workflow combines vision AI, ™ physically based rendering and simulation, ...
NVIDIA Brings AI Assistants to Life With GeForce RTX AI PCs
NVIDIA Brings AI Assistants to Life With GeForce RTX AI PCs Project G-Assist, NVIDIA ACE NIMs for Digital Humans, and Generative AI Tools Deliver Advanced AI Experiences on RTX Laptops; Plus, RTX-Accelerated APIs for Small Language Models Coming to Windows Copilot Runtime TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced new ™ technology to power AI assistants and digital humans running on new ™ AI laptops. NVIDIA unveiled Project G-Assist — an RTX-powered AI assistant technology demo that provides context-aware help for PC games and apps. The Project...
Computer Industry Joins NVIDIA to Build AI Factories and Data Centers ...
Computer Industry Joins NVIDIA to Build AI Factories and Data Centers for the Next Industrial Revolution Top Computer Manufacturers Unveil Array of Blackwell-Powered Systems Featuring Grace CPUs, NVIDIA Networking and InfrastructureBroad Portfolios Encompass Cloud, On-Premises, Embedded and Edge AI SystemsOfferings Range From Single to Multi-GPUs, x86 to Grace, Air to Liquid Cooling TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA and the world’s top computer manufacturers today unveiled an array of NVIDIA Blackwell architecture-powered systems featuring Grace CPUs, N...
NVIDIA Supercharges Ethernet Networking for Generative AI
NVIDIA Supercharges Ethernet Networking for Generative AI Spectrum-X Adopted by Cloud Service Providers, GPU Cloud Providers and Enterprises; Broad System-Maker Support Extends NVIDIA Networking’s Reach to Every Market TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced widespread adoption of the as well as an accelerated product release schedule. CoreWeave, GMO Internet Group, Lambda, Scaleway, STPX Global and Yotta are among the first AI cloud service providers embracing NVIDIA Spectrum-X to bring extreme networking performance to their AI infras...
NVIDIA NIM Revolutionizes Model Deployment, Now Available to Transform...
NVIDIA NIM Revolutionizes Model Deployment, Now Available to Transform World’s Millions of Developers Into Generative AI Developers 150+ Partners Across Every Layer of AI Ecosystem Embedding NIM Inference Microservices to Speed Enterprise AI Application Deployments From Weeks to MinutesNVIDIA Developer Program Members Gain Free Access to NIM for Research, Development and Testing TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced that the world’s 28 million developers can now download ™ — inference microservices that provide models as optimized cont...
NVIDIA Releases Digital Human Microservices, Paving Way for Future of ...
NVIDIA Releases Digital Human Microservices, Paving Way for Future of Generative AI Avatars NVIDIA ACE Now Generally Available for Cloud, in Early Access for RTX AI PCs, in Use by Companies Across Customer Service, Gaming and Healthcare, Including Dell Technologies, ServiceNow, Aww Inc., Inventec, Perfect World Games TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced the of NVIDIA ACE generative AI microservices to accelerate the next wave of digital humans, as well as new generative AI breakthroughs coming soon to the platform. Companies in cus...
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing P...
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Eight of 10 patients remain completely attack-free following the 16-week primary observation period through the latest follow-up, including patients with the most severe diseaseSingle dose of NTLA-2002 led to a 98% mean r...
BioCryst Presents New Real-world Evidence Showing Reductions in Attack...
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more tolerable HAE prophylaxis options RESEARCH TRIANGLE PARK, N.C., June 02, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function had a reduction in monthly...
Heineken® Celebrates Thousands of ‘Real Hardcore Fans’ by Helping Them...
Heineken® Celebrates Thousands of ‘Real Hardcore Fans’ by Helping Them Take Part in the UEFA Champions League Final Trophy Celebrations For The First Time Ever Heineken® says cheers to the Real Hardcore Fans as thousands of fans faces adorn the celebration confetti during the UEFA Champions League Final 2024 Trophy Lift at Wembley LONDON, June 01, 2024 (GLOBE NEWSWIRE) -- Tonight, Heineken® has created a way for thousands of ‘real hardcore fans’ to take part in the UEFA Champions League Final Trophy celebration, marking the culmination of the ‘’ 2024 campaign. Following the fina...
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Dur...
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing for more than 7 months and progression free survival (PFS) was 5.9 monthsObjective responses were also seen in 4 of 13 response-evaluable EGFR mutant (EGFRmut) NSCLC patients confirming the activity o...
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination wit...
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) Media Release COPENHAGEN, Denmark, and MAINZ, Germany; June 1, 2024 Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival (mOS) of 17.5 months in patients with previously treated PD-L1-positive mNSCLC treated with combination of acasunlimab with pembrolizumab every six weeksData from this ongoi...
Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in ...
Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom Erste Daten aus einer laufenden Phase-2-Studie zeigten eine 12-Monats-Gesamtüberlebensrate von 69 % und ein medianes Gesamtüberleben von 17,5 Monaten bei Patientinnen und Patienten mit vorbehandeltem, PD-L1-positivem, metastasiertem nicht-kleinzelligem Lungenkarzinom, die alle sechs Wochen mit einer Kombination aus Acasunlimab und Pembrolizumab behandelt wurden.Die Daten der laufenden Phase...
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination wit...
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic non-small cell lung cancer treated with a combination of acasunlimab and pembrolizumab every six weeksData from this ongoing Phase 2 study to inform the planned pivotal Ph...
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data ...
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 “trigger” (“window of opportunity”) investigator-sponsored trial demonstrated BDTX-1535 achieved clinically meaningful drug levels in brain tumor tissue CAMBRIDGE, Mass., June 01, 2024 (GLOBE NE...
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug C...
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024 An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacySYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses ≥ 1.2mg/KgNo dose limiting toxicities (DLTs) have been observed to date in doses up to and including 4.5 mg/Kg (cohort 7)...
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical...
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors - WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete response - - Monotherapy recommended dose for expansion selected and expansion arms open for enrollment - - Preliminary data on WTX-124 administered to patients i...
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and C...
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System Newly Launched Technology Will Be on Display at ASSFN in Nashville from June 1 - 4 SOLANA BEACH, Calif., June 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announces full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System at the from Saturday, June 1st – Tuesday, June 4th in Nashville....
Ultimovacs Announces Poster Presentation at the 2024 American Society ...
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting NON-REGULATORY PRESS RELEASE Oslo, June 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. The late-breaking abstract can be found on the 2024 ASCO website: /abstracts-presentations/232936...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.